Another preclinical paper on the Episealer implant published

Another preclinical paper has been published that again validates Episurf Medical’s (NASDAQ: EPIS B) patented cartilage repair technology to treat knee pain. The study titled “Cartilage Health in Knees Treated with Metal Resurfacing Implants or Untreated Focal Cartilage Lesions: A Preclinical Study in Sheep” by N. Martinez-Carranza et al. is now available online in the medical journal “Cartilage”. Whilst the paper looks at the positive impact of the Episealer knee implant, it also indicates that the biological coatings applied to the implant maintain the health of the surrounding cartilage, offering an excellent “chondrointegration” of cartilage to the Episealer.

“The coatings that are applied to the implant appear to result in the surrounding cartilage being nourished and maintained, which is unique. This is an exciting clinical validation of our technology and more evidence in this area is starting to become available”, comments Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical 

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: